My Portfolio
My Watchlists
Profile & Performance
Smart Portfolio
Find & Follow Experts
Top Lists
Top Experts
Make Better, Data Driven Investment Decisions
TipRanks tools are all you need to make data-driven investment decisions. Conduct comprehensive stock research, find new investment ideas, analyze your portfolio, and follow the best-performing Wall Street experts, with ease.
About Us
Plans & Pricing
Welcome

Analysts Have Conflicting Sentiments on These Healthcare Companies: Roche Holding AG (OtherRHHVF), Sanofi (OtherSNYNF) and BioNTech SE (BNTX)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Roche Holding AG (RHHVFResearch Report), Sanofi (SNYNFResearch Report) and BioNTech SE (BNTXResearch Report).

Roche Holding AG (RHHVF)

In a report released yesterday, Dominic Lunn from Credit Suisse maintained a Hold rating on Roche Holding AG, with a price target of CHF350.00. The company’s shares closed last Thursday at $374.99.

According to TipRanks.com, Lunn is ranked #4829 out of 7667 analysts.

Roche Holding AG has an analyst consensus of Moderate Buy, with a price target consensus of $405.97, an 8.5% upside from current levels. In a report issued on September 7, UBS also maintained a Hold rating on the stock with a CHF350.00 price target.

See today’s analyst top recommended stocks >>

Sanofi (SNYNF)

Deutsche Bank analyst Emmanuel Papadakis maintained a Sell rating on Sanofi today and set a price target of EUR80.00. The company’s shares closed last Thursday at $97.13.

According to TipRanks.com, Papadakis is a 3-star analyst with an average return of 2.1% and a 55.9% success rate. Papadakis covers the Healthcare sector, focusing on stocks such as Roche Holding AG, Roche Holding, and Grifols SA.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Sanofi with a $119.85 average price target.

BioNTech SE (BNTX)

In a report released today, Chris Shibutani from Goldman Sachs maintained a Hold rating on BioNTech SE, with a price target of $433.00. The company’s shares closed last Thursday at $355.05.

According to TipRanks.com, Shibutani is ranked #432 out of 7667 analysts.

Currently, the analyst consensus on BioNTech SE is a Moderate Buy with an average price target of $373.14, representing an 8.8% upside. In a report issued on September 21, H.C. Wainwright also reiterated a Hold rating on the stock with a $330.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on RHHVF: